Scientists trace heart failure drug's path through the body
NCT ID NCT07681479
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This Phase 1 trial investigates how the drug HRS-9057 is absorbed, processed, and eliminated in healthy men. Six participants receive a single dose, and researchers measure the drug and its breakdown products in blood, urine, and stool. The goal is to understand the drug's behavior in the body, which is a key step before testing it in people with fluid retention due to heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-9057
- What this could lead to
- If successful, this study could help determine the right dosing and safety of HRS-9057 for treating fluid retention in heart failure.
- What could go wrong
- This is a very early, small study in just 6 healthy people, not patients. It focuses on drug metabolism, not on whether the drug works for the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLUID RETENTION DUE TO HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital With Nanjing Medical University (Jiangsu Province Hospital )
Nanjing, Jiangsu, 210036, China